

North Central Cancer Treatment Group

N0572: A Phase I/II Study of Sorafenib and CCI-779 in Patients with Recurrent Glioblastoma

Revised Status Change – March 16, 2007

NOTICE OF STATUS CHANGE

This study is temporarily suspended to patient accrual effective Friday, March 16, 2007. Accrual to dose level 1 has been met.

Please retain this notice with the protocol.